Predictive Oncology Inc. (POAI)

NASDAQ: POAI · IEX Real-Time Price · USD
3.28
+0.12 (3.80%)
At close: Sep 27, 2023, 4:00 PM
3.13
-0.15 (-4.57%)
Pre-market: Sep 28, 2023, 7:10 AM EDT
3.8%
Market Cap 13.21M
Revenue (ttm) 1.55M
Net Income (ttm) -19.32M
Shares Out 4.03M
EPS (ttm) -4.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 6,625
Open 3.13
Previous Close 3.16
Day's Range 3.13 - 3.29
52-Week Range 2.47 - 13.88
Beta 1.52
Analysts n/a
Price Target n/a
Earnings Date Nov 9, 2023

About POAI

Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomi... [Read more]

Sector Healthcare
Founded 2002
Employees 31
Stock Exchange NASDAQ
Ticker Symbol POAI
Full Company Profile

Financial Performance

In 2022, POAI's revenue was $1.51 million, an increase of 5.97% compared to the previous year's $1.42 million. Losses were -$25.74 million, 30.9% more than in 2021.

Financial Statements

News

Predictive Oncology Reports Second Quarter 2023 Financial Results and Provides Business Update

Company to host investor call and webcast today, August 10th, at 5:30pm EDT Company to host investor call and webcast today, August 10th, at 5:30pm EDT

6 weeks ago - GlobeNewsWire

Predictive Oncology to Report Second Quarter 2023 Financial Results and Host Conference Call and Webcast on Thursday, August 10, 2023

EAGAN, Minn., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, ...

7 weeks ago - GlobeNewsWire

Predictive Oncology Announces Relocation of Corporate Headquarters to Pittsburgh

Surrounded by world renowned universities and medical centers, Predictive Oncology is part of the next generation of Pittsburgh's innovation ecosystem

2 months ago - GlobeNewsWire

Predictive Oncology Appoints Biopharmaceutical Finance Veteran Mr. Andrew Einhorn to its Business Advisory Board

EAGAN, Minn., June 27, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, ...

3 months ago - GlobeNewsWire

Predictive Oncology Appoints Dr. Bernard A. Harris, Jr. to its Newly Formed Business Advisory Board

EAGAN, Minn., June 20, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, ...

3 months ago - GlobeNewsWire

Predictive Oncology invited to present groundbreaking approach to drug discovery at the 2023 BIO International Convention

Pamela Bush, Chief Business Officer of Predictive Oncology, to discuss advancing pipelines and using patient heterogeneity with AI to solve the missing link in drug discovery Pamela Bush, Chief Busine...

4 months ago - GlobeNewsWire

Predictive Oncology Reports First Quarter 2023 Financial Results and Provides Business Update

Company to host investor call and webcast today, May 15th, at 5:30pm EDT Company to host investor call and webcast today, May 15th, at 5:30pm EDT

4 months ago - GlobeNewsWire

Predictive Oncology Announces Reverse Stock Split

Common Stock Will Begin Trading on Split-Adjusted Basis on April 24, 2023 EAGAN, Minn., April 20, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Compan...

5 months ago - GlobeNewsWire

Predictive Oncology Adjourns Special Meeting of Stockholders

MINNEAPOLIS, April 17, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, exten...

5 months ago - GlobeNewsWire

Predictive Oncology Announces Appointment of Oncology Translational Research Leader Christoph Reinhard, Ph.D., MBA, to its Scientific Advisory Board

EAGAN, Minn., April 04, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities,...

6 months ago - GlobeNewsWire

Predictive Oncology Announces Collaboration with Integra Therapeutics to Advance Gene Therapy

EAGAN, Minn., March 30, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a science-driven company on the leading edge of oncology drug discovery and development, today announces it is part...

6 months ago - GlobeNewsWire

Predictive Oncology Reports Year End 2022 Financial Results and Provides Business Update

EAGAN, Minn., March 21, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities,...

6 months ago - GlobeNewsWire

Predictive Oncology and Cancer Research Horizons have partnered to pursue development of cancer drugs

EAGAN, Minn., March 17, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) together with Cancer Research Horizons, the innovation engine at the core of the world's largest private funder...

6 months ago - GlobeNewsWire

Predictive Oncology Announces Distribution of Series F Preferred Stock to Holders of its Common Stock

EAGAN, Minn., March 16, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), today announced that its Board of Directors declared a dividend of on...

6 months ago - GlobeNewsWire

Predictive Oncology Engages LifeSci Advisors as Strategic Investor Relations Partner

Comprehensive, multi-faceted IR program to focus on raising awareness of Predictive Oncology and its portfolio of unique, proprietary assets capable of accelerating oncologic drug discovery and enabli...

7 months ago - GlobeNewsWire

Predictive Oncology Issues Letter to Shareholders

EAGAN, Minn., March 09, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities to ac...

7 months ago - GlobeNewsWire

Predictive Oncology and Cvergenx announce partnership to develop the first-ever genomics-based approach to precision radiation therapy and drug discovery using artificial intelligence

EAGAN, Minn., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) and Cvergenx, Inc. today announced an agreement to form a strategic partnership that has the potential to revolu...

7 months ago - GlobeNewsWire

Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer

EAGAN, Minn., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) is pleased to announce the appointment of Pamela Bush, Ph.D., MBA, as Chief Business Officer. Dr. Bush will lead...

8 months ago - GlobeNewsWire

Pioneer of Computational Biology Joins the Scientific Advisory Board of Predictive Oncology

EAGAN, Minn., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) today announced the appointment of Robert F. Murphy, Ph.D., to the company's Scientific Advisory Board where he ...

9 months ago - GlobeNewsWire

Distinguished Innovator in Genomics Joins the Scientific Advisory Board of Predictive Oncology

EAGAN, Minn., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) today announced the appointment of Marc Malandro, Ph.D., to the company's Scientific Advisory Board where he wil...

10 months ago - GlobeNewsWire

Predictive Oncology Appoints Leading Biopharma Executive Matthew J. Hawryluk Ph.D.

EAGAN, Minn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) is pleased to announce the appointment of Matthew J. Hawryluk, Ph.D., (www.predictive-oncology.com) to its Board...

10 months ago - GlobeNewsWire

Predictive Oncology Reports Third Quarter Financial Results

EAGAN, Minn., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) today announced the financial results for its third quarter ended September 30, 2022, which continue to reflect ...

11 months ago - GlobeNewsWire

David S. Smith appointed to the Board of Directors of Predictive Oncology

Leading authority on the therapeutic use of human tissues and cells Leading authority on the therapeutic use of human tissues and cells

1 year ago - GlobeNewsWire

Predictive Oncology Announces New Chief Executive Officer Raymond F. Vennare to Lead Company Growth

EAGAN, Minn., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) is pleased to announce the appointment of Raymond F. Vennare as Chief Executive Officer and Chairman of the Board, ef...

1 year ago - GlobeNewsWire

Predictive Oncology Strengthens Offerings with GMP Lab and Addition of Leading Expert in Formulation Development

EAGAN, Minn., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) today announced several key developments to further strengthen the company's offerings for pharmaceutical and biotec...

1 year ago - GlobeNewsWire